Xeris Biopharma(US:XERS) ZACKS·2025-02-26 16:05Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Xeris Biopharma, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Financial Expectations - Xeris Biopharma is expected to report a quarterly loss of $0.07 per share, reflecting a year-over-year change of +30% [3]. - Revenues are projected to be $60.59 million, representing a 36.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Xeris Biopharma is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.78%, suggesting a bullish outlook from analysts [10]. Earnings Surprise Prediction - A positive Earnings ESP reading is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [8][11]. - Xeris Biopharma's current Zacks Rank of 2 enhances the likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Xeris Biopharma was expected to post a loss of $0.09 per share but actually reported a loss of $0.06, achieving a surprise of +33.33% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13]. Industry Context - Esperion Therapeutics, another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.14 per share, with a year-over-year change of +72% and projected revenues of $70.01 million, up 117.1% from the previous year [17]. - Esperion's consensus EPS estimate has remained unchanged, but a lower Most Accurate Estimate has resulted in an Earnings ESP of -8.70%, combined with a Zacks Rank of 4 (Sell), making it difficult to predict an earnings beat [18].